drugset / Trial / NCT04276428

A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus

NCT04276428

Phase 1 Completed 28 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to evaluate the safety of a study drug known as LY3209590 in Japanese participants with type 2 diabetes. Side effects and tolerability will be documented. Blood samples will be taken to compare how the body handles the drug and how it affects blood sugar levels. The study will last almost five months for each participant.

Timeline

Start
2020-02-28
Primary completion
2020-11-28
Completion
2020-11-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Efsitora Alfa Protein / enzyme biologic Subcutaneous
Comparator insulin degludec Protein / enzyme biologic Subcutaneous